Bristol Myers Squibb Company
NEWS
Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.
BMS accused Kite and Gilead of copying the research conducted at Memorial Sloan Kettering to push the development of Yescarta.
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Bristol-Myers Squibb is looking to start 2020 on the right foot by filing a New Drug Application for its acute myeloid leukemia treatment CC-486 after data shows the medication extends survival time for AML patients.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
When Bristol-Myers Squibb acquired Celgene this year for $74 billion, one of the drugs it picked up was a CAR-T therapy, lisocabtagene maraleucel (liso-cel).
As usual, it was a busy week for clinical trial updates. Here’s a look.
With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.
JOBS
IN THE PRESS